New study tracks CF Drug's impact on Kids' lungs and lives
NCT ID NCT04613128
First seen Nov 03, 2025 · Last updated Jun 19, 2026 · Updated 40 times
Summary
This study followed 125 children aged 6-11 with cystic fibrosis who were prescribed a triple therapy (elexacaftor, tezacaftor, and ivacaftor). Researchers measured changes in sweat chloride, lung function, and weight over 24 months to see how well the treatment works in real life. The goal is to understand the therapy's benefits and help guide future care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611, United States
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Boston Children's Hospital, Brigham & Women's Hospital
Boston, Massachusetts, 02115, United States
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Children's Mercy Kansas City
Kansas City, Missouri, 64108, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
John Hopkins University
Baltimore, Maryland, 21287, United States
-
Oregon Health Sciences University
Portland, Oregon, 97239, United States
-
Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44146, United States
-
Riley Hospital for Children
Indianapolis, Indiana, 46202, United States
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
-
Stanford University Medical Center
Palo Alto, California, 94304, United States
-
The Minnesota Cystic Fibrosis Center
Minneapolis, Minnesota, 55455, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
-
Virginia Commonwealth University
Richmond, Virginia, 23219, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
elexacaftor, tezacaftor, and ivacaftor (triple combination therapy)
What this could lead to
If successful, this could show that the therapy improves lung function and quality of life in children with cystic fibrosis, guiding future treatments.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. The therapy is already FDA-approved for this age group, so the main goal is to understand real-world effects, not test a new cure.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.